Armata Pharmaceuticals (ARMP)
(Delayed Data from AMEX)
$2.56 USD
+0.02 (0.59%)
Updated Aug 8, 2024 10:00 AM ET
After-Market: $2.61 +0.05 (1.95%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARMP 2.56 +0.02(0.59%)
Will ARMP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARMP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARMP
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Tops Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
ARMP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why
Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
Other News for ARMP
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
Armata Pharmaceuticals receives $5.25M of funding from DoD
Armata Pharmaceuticals Updates Chief Medical Officer’s Compensation
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024